The European Patent Office (EPO) has published patent application EP3601341A1, titled 'Antibodies against the human FSHR extracellular domain'. This publication pertains to a specific invention related to therapeutic antibodies, with FSHR Theranostics listed as the applicant and Nicolae Ghinea as the inventor. The patent is classified under C07K (Peptides) and G01N (Investigating or analysing materials). The publication date is March 11, 2026, and it is designated for use in multiple European states.

This document is a patent publication, not a regulatory rule or guidance that imposes direct compliance obligations on companies. It signifies the granting of intellectual property rights for a specific technology. Companies operating in the pharmaceutical or biotechnology sectors, particularly those involved in antibody development or research related to the FSHR protein, should be aware of this patent for potential licensing, infringement, or competitive intelligence purposes. No immediate compliance actions are required based solely on this patent publication.